Wee Joo Chng

Research interests

Publications

• International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma

  Journal of Clinical Oncology · 2025 · https://doi.org/10.1200/jco-24-01893

• The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

  Leukemia · 2022 · https://doi.org/10.1038/s41375-022-01613-1

• The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

  Leukemia · 2022 · https://doi.org/10.1038/s41375-022-01620-2

• Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(20)30756-7

• Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

  The Lancet · 2018 · https://doi.org/10.1016/s0140-6736(18)33003-4

• Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

  Leukemia · 2017 · https://doi.org/10.1038/leu.2017.138

• Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30189-4

• Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

  Blood · 2016 · https://doi.org/10.1182/blood-2016-01-631200

• A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(15)00533-1

• International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30206-6

• Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse

  Blood · 2015 · https://doi.org/10.1182/blood-2015-05-646240

• Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)00464-7

• IMWG consensus on risk stratification in multiple myeloma

  Leukemia · 2013 · https://doi.org/10.1038/leu.2013.247

• New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

  Leukemia · 2013 · https://doi.org/10.1038/leu.2013.350

• A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

  Nature Medicine · 2012 · https://doi.org/10.1038/nm.2713

• Management of treatment-emergent peripheral neuropathy in multiple myeloma

  Leukemia · 2011 · https://doi.org/10.1038/leu.2011.346

• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

  Leukemia · 2011 · 10.1038/leu.2011.196

• Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma

  Cancer Cell · 2007 · https://doi.org/10.1016/j.ccr.2007.07.003

Current projects

No projects listed.